Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06926842 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

A Phase 2 study of Obesity and Type 2 Diabetes, sponsored by Zealand Pharma.

Active
Registry status
Phase 2
Development phase
221
Enrollment target
20
Study locations

NCT06926842 is a Phase 2 study of Obesity and Type 2 Diabetes that is active but no longer recruiting, run by Zealand Pharma. The registered enrollment target is 221 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06926842, a Phase 2 study of Obesity and Type 2 Diabetes, is active but no longer recruiting, sponsored by Zealand Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
221 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.

Conditions Studied

Obesity Type 2 Diabetes Overweight

Interventions

  • OTHER Placebo
  • DRUG Petrelintide

Study Locations (20)

Florida

  • Innovative Research of West Florida - Clearwater
  • East Coast Institute for Research, LLC - Jacksonville
  • Solutions Through Advanced Research, Inc - Jacksonville
  • M3 Wake Research - Lake City - Lake City
  • West Orange Endocrinology P.A - Ocoee
  • Palm Beach Research Center - West Palm Beach

California

  • Velocity Clinical Research - Huntington Park
  • Velocity Clinical Research, North Hollywood - North Hollywood
  • Exalt Clinical Research - San Diego
  • Diablo Clinical Research Inc. - Walnut Creek

Arizona

  • AZ Endocrine Institute - Chandler
  • Elite Clinical Studies, LLC - Phoenix
  • M3 Wake Research, Tucson Neuroscience Research, LLC - Tucson

Georgia

  • M3 Wake Research - Atlanta - Atlanta
  • East Coast Institute for Research - Canton - Canton
  • Privia Medical Group Georgia, LLC - Savannah

Alabama

  • Cullman Clinical Trials - Family Medicine - Cullman

Arkansas

  • Medical Investigation Inc - Little Rock

Connecticut

  • Chase Medical Research, LLC - Waterbury

District of Columbia

  • Emerson Clinical Research - Washington D.C.

Trial Details

FieldValue
Enrollment Target 221 participants
Start Date 2025-04-22
Est. Completion 2026-08-13
Phase Phase 2

Sponsor

Zealand Pharma

18 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06926842

The ClinicalTrials.gov registry entry for NCT06926842 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (73% lower). The listed sponsor is Zealand Pharma, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06926842 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT06926842 about?

NCT06926842 is a clinical study titled "Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)". The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.

What is the current status of trial NCT06926842?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2025-04-22. Estimated completion is 2026-08-13.

What conditions does trial NCT06926842 study?

This clinical trial studies the following conditions: Obesity, Type 2 Diabetes, Overweight.

What interventions are being tested in trial NCT06926842?

The interventions under investigation include: Placebo (OTHER), Petrelintide (DRUG).

Who is sponsoring clinical trial NCT06926842?

This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06926842 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Type 2 Diabetes

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.